Reaching for the stars: a wider perspective for designing future cardiovascular outcome trials of triglyceride-lowering therapies

Graphical AbstractCategories of hypertriglyceridaemia, associated triglyceride-rich lipoproteins, corresponding risk of major adverse cardiovascular events, and implications for triglyceride-lowering cardiovascular outcome trials. ANGPTL3, angiopoietin-like protein 3; ApoC3: apolipoprotein C-III; CE, cholesteryl ester; CM, chylomicron; CVOT, cardiovascular outcome trials; FCS, familial chylomicronemia syndrome; HTG, hypertriglyceridaemia; IDL, intermediate-density lipoprotein; MACE, major adverse cardiovascular events; MCS, multifactorial chylomicronemia syndrome; TG, triglyceride; VLDL, very-low-density lipoprotein.Open in new tabDownload slide